Frazier Life Sciences — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Parabilis Medicinesparabilismed.cominNASDAQ: PBLSJan 2026
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalGeneral CatalystNextech InvestRA Capital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.